Argenx Se (ARGX) Gross Margin (2022 - 2026)
Argenx Se (ARGX) posted Gross Margin of 90.68% for Q1 2026, up 2.63% on a QoQ basis from 88.36% in Q4 2025, and up 93.0% year-over-year from 46.98% in Q1 2025.
Argenx Se (ARGX) Gross Margin (2022 - 2026) Analysis & Trends
Argenx Se's Gross Margin history runs 5 years deep, the most recent figure standing at 90.68% for Q1 2026.
- Quarterly Gross Margin rose 93.0% year-over-year to 90.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.46% (down 25.0% YoY) and the FY2025 annual result came in at 89.14%, down 46.0% from the prior year.
- Gross Margin was 90.68% for Q1 2026 at Argenx Se, up from 88.36% in the prior quarter.
- Across five years, Gross Margin topped out at 93.52% in Q1 2022 and bottomed at 88.33% in Q2 2025.
- A 5-year average of 90.48% and a median of 90.14% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 317 bps — and 2026, when it soared 93 bps.
- Argenx Se's Gross Margin stood at 92.63% in 2022, then declined by 3 bps to 89.45% in 2023, then climbed by 1 bps to 90.14% in 2024, then fell by 2 bps to 88.36% in 2025, then increased by 3 bps to 90.68% in 2026.
- Business Quant data shows ARGX's Gross Margin at 90.68% in Q1 2026, 88.36% in Q4 2025, and 90.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 90.68% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 82.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.68% |
| Dec 31, 2025 | 88.36% |
| Sep 30, 2025 | 90.29% |
| Jun 30, 2025 | 88.33% |
| Mar 31, 2025 | 89.75% |
| Dec 31, 2024 | 90.14% |
| Sep 30, 2024 | 89.69% |
| Jun 30, 2024 | 89.03% |
| Mar 31, 2024 | 89.16% |
| Dec 31, 2023 | 89.45% |
| Sep 30, 2023 | 89.06% |
| Jun 30, 2023 | 91.08% |
| Mar 31, 2023 | 91.59% |
| Dec 31, 2022 | 92.63% |
| Sep 30, 2022 | 92.18% |
| Jun 30, 2022 | 93.31% |
| Mar 31, 2022 | 93.52% |